4-phospho-d-erythronohydroxamic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	449303
CHEMBL ID	116018
SCHEMBL ID	2219243
MeSH ID	M0508452

Synonyms (17)

Synonym
phosphoric acid mono-((1r,3r)-2,3-dihydroxy-3-hydroxycarbamoyl-propyl) ester
bdbm50148767
2,3-dihydroxy-4-(hydroxyamino)-4-oxobutyl dihydrogen phosphate
4-phospho-d-erythronohydroxamic acid
RES ,
DB04496 ,
2BES
[(2r,3r)-2,3-dihydroxy-4-(hydroxyamino)-4-oxobutyl] dihydrogen phosphate
CHEMBL116018 ,
718599-64-5
SCHEMBL2219243
DTXSID10332304
(2r,3r)-2,3-dihydroxy-4-(hydroxyamino)-4-oxobutyl dihydrogen phosphate
PD059244
(2r,3r)-2,3-dihydroxy-4-(hydroxyamino)-4-oxobutyldihydrogenphosphate
1310908-09-8
rel-(2r,3r)-2,3-dihydroxy-4-(hydroxyamino)-4-oxobutyl dihydrogen phosphate

Research Excerpts

Bioavailability

Excerpt	Reference	Relevance
" A virtual fragment screen was undertaken of the enzyme to discover starting points for the development of inhibitors which are likely to have appropriate physicochemical properties for an orally bioavailable compound."	( Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase. Alibu, VP; Barrett, MP; Brenk, R; Campbell, G; Gilbert, IH; Ruda, GF, 2010)	0.36

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
6-phosphogluconate dehydrogenase, decarboxylating	Ovis aries (sheep)	Ki	2.5400	2.5400	2.5400	2.5400	AID492275
6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)	Ki	1.2750	0.0100	2.7450	8.3000	AID7236; AID7238
6-phosphogluconate dehydrogenase, decarboxylating	Trypanosoma brucei brucei TREU927	Ki	0.0100	0.0100	0.0100	0.0100	AID594837
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Process	via Protein(s)	Taxonomy
pentose-phosphate shunt	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
pentose-phosphate shunt, oxidative branch	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
pentose biosynthetic process	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
D-gluconate catabolic process	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Process	via Protein(s)	Taxonomy
phosphogluconate dehydrogenase (decarboxylating) activity	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
NADP binding	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Process	via Protein(s)	Taxonomy
nucleus	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
cytosol	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
extracellular exosome	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
cytosol	6-phosphogluconate dehydrogenase, decarboxylating	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay ID	Title	Year	Journal	Article
AID215359	In vitro antiparasitic activity was determined against Trypanosoma brucei	2004	Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13	Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues.
AID7236	Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli	2004	Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13	Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues.
AID492275	Inhibition of sheep 6PGDH expressed in Escherichia coli by spectroscopy	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase.
AID594837	Inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Enediol mimics as inhibitors of the D-arabinose 5-phosphate isomerase (KdsD) from Francisella tularensis.
AID7238	Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver	2004	Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13	Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues.
AID229393	Selectivity ratio of inhibition constant of compound against 6-phosphogluconate dehydrogenase of sheep to 6-phosphogluconate dehydrogenase of Trypanosoma brucei	2004	Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13	Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues.
AID1693212	Competitive inhibition of recombinant poly-His-tagged Trypanosoma cruzi Ribose 5-phosphate isomerase type B expressed in Escherichia coli BL21 codon plus (DE3) using ribose 5-phosphate as substrate
AID158531	In vitro antiparasitic activity against Plasmodium falciparum	2004	Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13	Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues.
AID594838	Inhibition of Mycobacterium tuberculosis rpiB	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Enediol mimics as inhibitors of the D-arabinose 5-phosphate isomerase (KdsD) from Francisella tularensis.
AID213662	In vitro antiparasitic activity was determined against Trypanosoma cruzi	2004	Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13	Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues.
AID99666	In vitro cytotoxic activity against L6 cells	2004	Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13	Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues.
AID1126501	Binding affinity to Pseudomonas aeruginosa KdsD expressed Escherichia coli at 5 mM after 2 to 3 days by STD-NMR analysis	2014	Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8	Arabinose 5-phosphate isomerase as a target for antibacterial design: studies with substrate analogues and inhibitors.
AID492273	Inhibition of Trypanosoma brucei 6PGDH expressed in Escherichia coli by spectroscopy	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase.
AID100416	In vitro antiparasitic activity was determined against Leishmania donovani	2004	Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13	Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues.
AID594836	Inhibition of Francisella tularensis N-terminal hexahistidine-tagged arabinose phosphate isomerase expressed in Escherichia coli BL21(DE3) after 3 hrs	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Enediol mimics as inhibitors of the D-arabinose 5-phosphate isomerase (KdsD) from Francisella tularensis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	1 (20.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.72 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.51 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.72)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
phosphoglycolohydroxamate phosphoglycolohydroxamate: inhibits DHAP (dihydroxyacetone phosphate)-converting enzymes; structure. phosphoglycolohydroxamic acid : The hydroxamate of phosphoglycolic acid.	2.06	1	amidoalkyl phosphate; hydroxamic acid	EC 5.3.1.1 (triose-phosphate isomerase) inhibitor
phenylmethanesulfonic acid phenylmethanesulfonic acid: RN given refers to parent cpd	2.05	1
cysteic acid Cysteic Acid: Beta-Sulfoalanine. An amino acid with a C-terminal sulfonic acid group which has been isolated from human hair oxidized with permanganate. It occurs normally in the outer part of the sheep's fleece, where the wool is exposed to light and weather.. cysteic acid : An amino sulfonic acid that is the sulfonic acid analogue of cysteine.	2.05	1	alanine derivative; amino sulfonic acid; carboxyalkanesulfonic acid; cysteine derivative; non-proteinogenic alpha-amino acid	animal metabolite
4-phosphoerythronate 4-phosphoerythronate: inhibits ribose-5-phosphate isomerase. 4-phospho-D-erythronic acid : The D-enantiomer of 4-phosphoerythronic acid.	2.73	3	4-phosphoerythronic acid	Escherichia coli metabolite; mouse metabolite
Thieno[3,2-b]thiophene-2-carboxylic acid [no description available]	2.05	1	thienothiophene

Condition	Indicated	Relationship Strength	Studies	Trials
African Sleeping Sickness [description not available]	0	2.05	1	0
Trypanosomiasis, African A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.	0	2.05	1	0

chemdatabank.com